Conference Preview: 2026 EADV Congress in Vienna

HCPLive will provide on-site coverage of the 2026 European Academy of Dermatology and Venereology (EADV) Congress, held September 30 to October 3 at the Austria Center Vienna, featuring late-breaking trial data and interviews with dermatology leaders.¹,²

The congress returns to Vienna for the third time, following editions in 2007 and 2016, and organizers expect more than 17,000 attendees.³ This year's program includes late-breaking abstracts and poster presentations across prurigo nodularis, alopecia areata, hidradenitis suppurativa, atopic dermatitis, and psoriasis.

Over the course of this 4-day meeting, dermatologists, venereologists, researchers, and other skin health professionals from around the world will convene to review late-breaking clinical trial data, updated guidance, and evolving treatment strategies across the full spectrum of dermatologic disease.

What to Expect at EADV 2026 in Vienna:

This year's program features late-breaking abstracts, poster presentations, and educational sessions spanning prurigo nodularis, alopecia areata, hidradenitis suppurativa, atopic dermatitis, psoriasis, vitiligo, chronic hand eczema, and the growing role of artificial intelligence (AI) in clinical practice.

HCPLive will be on-site throughout the congress, providing exclusive interviews with dermatology leaders, coverage of notable sessions, and reporting on the latest clinical data shared during the meeting.

Key Interviews at EADV:

• Neal Bhatia, MD
• Martina Porter, MD
• Leon Kircik, MD
• Iltefat Hamzavi, MD
• Christopher Bunick, MD, PhD
• Brett King, MD
• Shuguang Yuan, MD
• Mark Lebwohl, MD

Late-Breaking Data to Watch:

• Oturkibart in prurigo nodularis: 52-week results from a phase 3 trial in adults
• Ritlecitinib (Litfulo) in alopecia areata: 5-year results from the phase 3 ALLEGRO-LT study in patients with at least 25% scalp hair loss, analyzed by severity
• Abdakibart in hidradenitis suppurativa: week 16 efficacy and safety of this anti-interleukin (IL)-1β agent from the phase 2 placebo-controlled LOTUS trial, including IHS4 subgroup and lesion-type analyses
• Lebrikizumab (Ebglyss) in atopic hand and foot dermatitis: 16-week results from the randomized, double-blind, placebo-controlled ADTouch trial
• EVO301 in atopic dermatitis: top-line phase 2a proof-of-concept data for this novel IL-18 binding protein in moderate to severe disease
• Icotrokinra in high-impact site psoriasis: 2-year durability and safety findings from the ICONIC-TOTAL randomized controlled trial

Poster Presentations to Watch:

• Stapokibart in adolescents with moderate to severe atopic dermatitis: long-term open-label extension results from a phase 3 trial
• Rezpegaldesleukin in severe to very severe alopecia areata: 52-week results from the phase 2b REZOLVE-AA study
• Picankibart in plaque psoriasis: efficacy across body mass index and body weight subgroups from the phase 3 CLEAR-2 study
• Izokibep in moderate to severe hidradenitis suppurativa: patient subgroup analysis from a phase 3 study of this IL-17A inhibitor
• SHR-1819 in prurigo nodularis: phase 2 results from a multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial

Sessions to Watch:

Among the many sessions on this year's agenda, the following offer practical updates for clinicians attending the congress.

Skin of Color Society (SOCS)

Wednesday, September 30 • 08:30–10:00 CEST • Hall F2

Overview: Given the diverse skin types dermatologists encounter worldwide, this session will focus on recognizing the distinct presentations of skin disease in patients with skin of color. Speakers will cover nuances in skin of color dermatology, practical management of hidradenitis suppurativa, new developments in vitiligo management, and the varied manifestations of facial pigmentation.

Treating Psoriasis

Thursday, October 1 • 10:15–11:45 CEST • Hall A

Overview: This session will bring attendees up to date on the most relevant psoriasis developments, guidelines, and practical knowledge from the past year. Talks will summarize the current understanding of treatment before reviewing recent advances and their impact on clinical practice.

Chronic Hand Eczema

Thursday, October 1 • 10:15–11:45 CEST • Hall F1

Overview: Designed as a focused update, this session will review the latest developments and guidance in chronic hand eczema from the past year. Speakers will outline current disease understanding and discuss how recent treatment advances translate to everyday care.

Atopic Dermatitis: Clinical Variants and Treatment Recommendations

Thursday, October 1 • 14:15–15:45 CEST • Hall K

Overview: This session will examine clinical variants of atopic dermatitis alongside current treatment recommendations. Attendees will hear a summary of the past year's key developments and guideline updates, followed by a review of recent advances and their implications for practice.

AI Strategies in Dermatological Practice

Friday, October 2 • 08:30–10:00 CEST • Hall E1

Overview: As AI tools become more common in clinical settings, this session will review the most relevant recent developments in AI for dermatology. Talks will cover the current state of the field and explore how emerging applications may affect clinical practice.

The HCPLive team will provide ongoing coverage from Vienna, including session highlights, expert interviews, and key clinical takeaways from the EADV Congress 2026.

Editor's note: This summary was created with the help of AI tools.

References

1. European Academy of Dermatology and Venereology. EADV Congress 2026. Accessed September 23, 2026. https://eadv.org/congress/.

2. European Academy of Dermatology and Venereology. The venue of EADV Congress 2026. Accessed September 23, 2026. https://eadv.org/congress/about/the-venue/.

3. Vienna Convention Bureau. Vienna to welcome 17,000 dermatology experts in 2026. Published July 21, 2025. Accessed September 23, 2026. https://meeting.vienna.info/en/current/news-en/eadv-2026-wien-951686.